JP2014510737A - 標的細胞による治療薬の取り込みを高めるための方法及び組成物 - Google Patents
標的細胞による治療薬の取り込みを高めるための方法及び組成物 Download PDFInfo
- Publication number
- JP2014510737A JP2014510737A JP2014501425A JP2014501425A JP2014510737A JP 2014510737 A JP2014510737 A JP 2014510737A JP 2014501425 A JP2014501425 A JP 2014501425A JP 2014501425 A JP2014501425 A JP 2014501425A JP 2014510737 A JP2014510737 A JP 2014510737A
- Authority
- JP
- Japan
- Prior art keywords
- use according
- caveolae
- cancer
- lipid raft
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 37
- 229940124597 therapeutic agent Drugs 0.000 title claims abstract description 24
- 238000000034 method Methods 0.000 title abstract description 13
- 239000000203 mixture Substances 0.000 title abstract description 9
- 230000002708 enhancing effect Effects 0.000 title abstract description 6
- 150000002632 lipids Chemical class 0.000 claims abstract description 49
- 230000037361 pathway Effects 0.000 claims abstract description 43
- 230000027448 caveolin-mediated endocytosis Effects 0.000 claims abstract description 36
- 210000004027 cell Anatomy 0.000 claims abstract description 32
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 10
- 108010079505 Endostatins Proteins 0.000 claims description 159
- 102400001047 Endostatin Human genes 0.000 claims description 158
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 claims description 139
- 229960000988 nystatin Drugs 0.000 claims description 134
- 206010028980 Neoplasm Diseases 0.000 claims description 48
- 102000001301 EGF receptor Human genes 0.000 claims description 40
- 108060006698 EGF receptor Proteins 0.000 claims description 40
- 230000002401 inhibitory effect Effects 0.000 claims description 27
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 claims description 22
- 229960003942 amphotericin b Drugs 0.000 claims description 19
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 claims description 18
- 210000004881 tumor cell Anatomy 0.000 claims description 16
- 230000004614 tumor growth Effects 0.000 claims description 14
- 229960005395 cetuximab Drugs 0.000 claims description 13
- 239000003112 inhibitor Substances 0.000 claims description 13
- NBBJYMSMWIIQGU-UHFFFAOYSA-N Propionic aldehyde Chemical compound CCC=O NBBJYMSMWIIQGU-UHFFFAOYSA-N 0.000 claims description 12
- 230000033115 angiogenesis Effects 0.000 claims description 12
- 239000007928 intraperitoneal injection Substances 0.000 claims description 9
- 230000035168 lymphangiogenesis Effects 0.000 claims description 9
- 239000002202 Polyethylene glycol Substances 0.000 claims description 8
- 229920001427 mPEG Polymers 0.000 claims description 8
- 229920001223 polyethylene glycol Polymers 0.000 claims description 8
- 102000005853 Clathrin Human genes 0.000 claims description 7
- 108010019874 Clathrin Proteins 0.000 claims description 7
- 229940121375 antifungal agent Drugs 0.000 claims description 7
- 210000004323 caveolae Anatomy 0.000 claims description 7
- 229930193282 clathrin Natural products 0.000 claims description 7
- 201000010099 disease Diseases 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 238000001990 intravenous administration Methods 0.000 claims description 7
- YZOUYRAONFXZSI-SBHWVFSVSA-N (1S,3R,5R,6R,8R,10R,11R,13R,15R,16R,18R,20R,21R,23R,25R,26R,28R,30R,31S,33R,35R,36R,37S,38R,39S,40R,41S,42R,43S,44R,45S,46R,47S,48R,49S)-5,10,15,20,25,30,35-heptakis(hydroxymethyl)-37,39,40,41,42,43,44,45,46,47,48,49-dodecamethoxy-2,4,7,9,12,14,17,19,22,24,27,29,32,34-tetradecaoxaoctacyclo[31.2.2.23,6.28,11.213,16.218,21.223,26.228,31]nonatetracontane-36,38-diol Chemical group O([C@@H]([C@H]([C@@H]1OC)OC)O[C@H]2[C@@H](O)[C@@H]([C@@H](O[C@@H]3[C@@H](CO)O[C@@H]([C@H]([C@@H]3O)OC)O[C@@H]3[C@@H](CO)O[C@@H]([C@H]([C@@H]3OC)OC)O[C@@H]3[C@@H](CO)O[C@@H]([C@H]([C@@H]3OC)OC)O[C@@H]3[C@@H](CO)O[C@@H]([C@H]([C@@H]3OC)OC)O3)O[C@@H]2CO)OC)[C@H](CO)[C@H]1O[C@@H]1[C@@H](OC)[C@H](OC)[C@H]3[C@@H](CO)O1 YZOUYRAONFXZSI-SBHWVFSVSA-N 0.000 claims description 6
- 229920000858 Cyclodextrin Polymers 0.000 claims description 6
- ZTQSAGDEMFDKMZ-UHFFFAOYSA-N butyric aldehyde Natural products CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 claims description 6
- 239000007924 injection Substances 0.000 claims description 6
- 238000002347 injection Methods 0.000 claims description 6
- 201000007270 liver cancer Diseases 0.000 claims description 6
- 208000014018 liver neoplasm Diseases 0.000 claims description 6
- 230000004651 endocytosis pathway Effects 0.000 claims description 5
- 230000001419 dependent effect Effects 0.000 claims description 4
- 239000002502 liposome Substances 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 206010025323 Lymphomas Diseases 0.000 claims description 3
- 230000001159 endocytotic effect Effects 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 150000004291 polyenes Chemical class 0.000 claims description 3
- 206010005949 Bone cancer Diseases 0.000 claims description 2
- 208000018084 Bone neoplasm Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 208000003445 Mouth Neoplasms Diseases 0.000 claims description 2
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 claims description 2
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 206010039491 Sarcoma Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 238000010521 absorption reaction Methods 0.000 claims description 2
- 239000003429 antifungal agent Substances 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims description 2
- 238000005538 encapsulation Methods 0.000 claims description 2
- 201000004101 esophageal cancer Diseases 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 201000011066 hemangioma Diseases 0.000 claims description 2
- 210000002767 hepatic artery Anatomy 0.000 claims description 2
- 239000007927 intramuscular injection Substances 0.000 claims description 2
- 238000010255 intramuscular injection Methods 0.000 claims description 2
- 238000010253 intravenous injection Methods 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 201000011519 neuroendocrine tumor Diseases 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 238000007920 subcutaneous administration Methods 0.000 claims description 2
- 239000007929 subcutaneous injection Substances 0.000 claims description 2
- 238000010254 subcutaneous injection Methods 0.000 claims description 2
- 150000001413 amino acids Chemical group 0.000 claims 3
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- 230000001965 increasing effect Effects 0.000 abstract description 27
- 230000001225 therapeutic effect Effects 0.000 abstract description 10
- 239000002246 antineoplastic agent Substances 0.000 abstract description 7
- 239000003795 chemical substances by application Substances 0.000 abstract description 4
- 238000012216 screening Methods 0.000 abstract description 3
- 238000011282 treatment Methods 0.000 description 50
- 210000002889 endothelial cell Anatomy 0.000 description 35
- 230000012202 endocytosis Effects 0.000 description 16
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 14
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 14
- 238000010171 animal model Methods 0.000 description 12
- 238000002648 combination therapy Methods 0.000 description 11
- 229940079593 drug Drugs 0.000 description 11
- 230000002596 correlated effect Effects 0.000 description 10
- 239000002609 medium Substances 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 238000001262 western blot Methods 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- 238000003384 imaging method Methods 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 7
- 229910002092 carbon dioxide Inorganic materials 0.000 description 7
- 239000001569 carbon dioxide Substances 0.000 description 7
- 235000012000 cholesterol Nutrition 0.000 description 7
- 231100000673 dose–response relationship Toxicity 0.000 description 7
- 230000010595 endothelial cell migration Effects 0.000 description 7
- 230000007246 mechanism Effects 0.000 description 7
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 description 7
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 7
- 230000005747 tumor angiogenesis Effects 0.000 description 7
- 210000003556 vascular endothelial cell Anatomy 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 230000002159 abnormal effect Effects 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 230000000492 lymphangiogenic effect Effects 0.000 description 5
- 230000010534 mechanism of action Effects 0.000 description 5
- 239000013642 negative control Substances 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 241000699660 Mus musculus Species 0.000 description 4
- 125000003275 alpha amino acid group Chemical group 0.000 description 4
- 230000000843 anti-fungal effect Effects 0.000 description 4
- 230000000259 anti-tumor effect Effects 0.000 description 4
- 210000000170 cell membrane Anatomy 0.000 description 4
- 230000012292 cell migration Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 210000005073 lymphatic endothelial cell Anatomy 0.000 description 4
- 238000011580 nude mouse model Methods 0.000 description 4
- 239000002459 polyene antibiotic agent Substances 0.000 description 4
- 230000019491 signal transduction Effects 0.000 description 4
- 239000011550 stock solution Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 230000002491 angiogenic effect Effects 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 230000001086 cytosolic effect Effects 0.000 description 3
- 244000144993 groups of animals Species 0.000 description 3
- 201000005249 lung adenocarcinoma Diseases 0.000 description 3
- 210000004924 lung microvascular endothelial cell Anatomy 0.000 description 3
- 238000010232 migration assay Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 2
- RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 description 2
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 2
- 102000009193 Caveolin Human genes 0.000 description 2
- 108050000084 Caveolin Proteins 0.000 description 2
- DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000005754 cellular signaling Effects 0.000 description 2
- 230000006395 clathrin-mediated endocytosis Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 230000002121 endocytic effect Effects 0.000 description 2
- DNVPQKQSNYMLRS-SOWFXMKYSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@]3([C@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-SOWFXMKYSA-N 0.000 description 2
- 238000000799 fluorescence microscopy Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000012216 imaging agent Substances 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
- 239000012130 whole-cell lysate Substances 0.000 description 2
- PCTMTFRHKVHKIS-BMFZQQSSSA-N (1s,3r,4e,6e,8e,10e,12e,14e,16e,18s,19r,20r,21s,25r,27r,30r,31r,33s,35r,37s,38r)-3-[(2r,3s,4s,5s,6r)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-19,25,27,30,31,33,35,37-octahydroxy-18,20,21-trimethyl-23-oxo-22,39-dioxabicyclo[33.3.1]nonatriaconta-4,6,8,10 Chemical compound C1C=C2C[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2.O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 PCTMTFRHKVHKIS-BMFZQQSSSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- -1 AMB (25-50 μg / mL) Chemical compound 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 241001480043 Arthrodermataceae Species 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 201000002909 Aspergillosis Diseases 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 208000036641 Aspergillus infections Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 102000019260 B-Cell Antigen Receptors Human genes 0.000 description 1
- 108010012919 B-Cell Antigen Receptors Proteins 0.000 description 1
- 206010004593 Bile duct cancer Diseases 0.000 description 1
- 241000335423 Blastomyces Species 0.000 description 1
- 102000001893 Bone Morphogenetic Protein Receptors Human genes 0.000 description 1
- 108010040422 Bone Morphogenetic Protein Receptors Proteins 0.000 description 1
- 102100037086 Bone marrow stromal antigen 2 Human genes 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 102000009016 Cholera Toxin Human genes 0.000 description 1
- 108010049048 Cholera Toxin Proteins 0.000 description 1
- 108010001463 Collagen Type XVIII Proteins 0.000 description 1
- 102000047200 Collagen Type XVIII Human genes 0.000 description 1
- 206010011486 Cryptococcal infections Diseases 0.000 description 1
- 201000007336 Cryptococcosis Diseases 0.000 description 1
- 241000221204 Cryptococcus neoformans Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012434 Dermatitis allergic Diseases 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 102000017914 EDNRA Human genes 0.000 description 1
- 101150062404 EDNRA gene Proteins 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- 102000018691 Focal Adhesion Kinase 1 Human genes 0.000 description 1
- 108010091824 Focal Adhesion Kinase 1 Proteins 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 241000228402 Histoplasma Species 0.000 description 1
- 101000740785 Homo sapiens Bone marrow stromal antigen 2 Proteins 0.000 description 1
- 108010042918 Integrin alpha5beta1 Proteins 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 102000003939 Membrane transport proteins Human genes 0.000 description 1
- 108090000301 Membrane transport proteins Proteins 0.000 description 1
- 241001480037 Microsporum Species 0.000 description 1
- 241000235395 Mucor Species 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 206010052399 Neuroendocrine tumour Diseases 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010034650 Peritoneal adhesions Diseases 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 102000016715 Transforming Growth Factor beta Receptors Human genes 0.000 description 1
- 108010092867 Transforming Growth Factor beta Receptors Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229940098178 ambisome Drugs 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical class OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 208000026900 bile duct neoplasm Diseases 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004900 c-terminal fragment Anatomy 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 239000002771 cell marker Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000015861 cell surface binding Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000037304 dermatophytes Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 210000001650 focal adhesion Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 150000002339 glycosphingolipids Chemical class 0.000 description 1
- 231100000086 high toxicity Toxicity 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000009061 membrane transport Effects 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 208000016065 neuroendocrine neoplasm Diseases 0.000 description 1
- 238000009522 phase III clinical trial Methods 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000723 toxicological property Toxicity 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/065—Diphenyl-substituted acyclic alcohols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/718—Starch or degraded starch, e.g. amylose, amylopectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Marine Sciences & Fisheries (AREA)
- Dermatology (AREA)
- Dispersion Chemistry (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
【選択図】 図1
Description
本発明の前述の各態様における特定の実施形態において、脂質ラフト/カベオラ依存性エンドサイトーシス経路の調節剤は、脂質ラフト/カベオラ依存性エンドサイトーシス経路の阻害剤である。このような阻害剤の例は、ポリエン系抗真菌薬(例えば、NT又はAMB)、メチル−β−シクロデキストリン、又はフィリピンである。
ヒト微小血管内皮細胞(HMEC)はATCC(受託番号CRL10636)から入手した。マウスリンパ管内皮細胞(mLEC)は、不完全フロイントアジュバントによって誘導される腹膜リンパ腫の消化により単離した(Zhuo W.ら、Journal of Pathology;222:249〜260)。EnduはSimcere−Medgenn Bio−pharmaceutical Co., Ltd.,から入手した。Enduは、N末端に付加的なアミノ酸配列(M)GGSHHHHHを含む組換えESであり、この配列は配列番号3又は配列番号4である。その最初のアミノ酸残基Mが大腸菌(E.Coli)で発現する際に任意に削除されるためである。ESはProtgen Ltd.から入手し、このアミノ配列は配列番号1又は配列番号2である。その最初のアミノ酸残基Mが大腸菌で発現する際に任意に削除されるためである。20kDaの平均分子量を有するメトキシPEGプロピオンアルデヒド(mPEG−ALD)(Jenkem Technology Co., Ltd.,)は、タンパク質のN末端でαアミノ基を特異的に修飾するPEG試薬として使用した。PEG−ES及びPEG−Enduは、PEG試薬キットで提供される使用説明書にしたがってProtgen Ltd.により調製した。ESのモノクローナル抗体は、Oncogene Science,Inc.から購入した。NT及び他の試薬はSigma−Aldrich Co.から購入した。
Kimら(2002)は、ESが、細胞外調節プロテインキナーゼ(ERK)、p38マイトジェン活性化プロテインキナーゼ(MAPK)、及びp125接着斑キナーゼ(p125FAK)によって媒介される内皮細胞におけるシグナル伝達経路を阻害し、その結果、内皮細胞活動を阻害することを発見した(Kimら、J.Biol.Chem.、2002、277、27872〜27879)。本実施例において、ERK及びp38MAPK経路は内皮細胞活性化のマーカーとされ、NTとESの併用によって、これらの経路に対するESの阻害効果がさらに上昇することが発見されている。
細胞遊走アッセイ:HMEC(1ウェルあたり細胞2×104個)を、トランスウェルチャンバー(Transwell chambers)(8μm孔、Costar)の上層に、0.5%FBS(Hyclone)及び10ng/mLのVEGF(PeproTech)を含むDMEM(Hyclone)にまいた。ES(40μg/mL)又はNT(50μg/mL)を、上層及び下層に添加し、その後、このチャンバーを37℃で6時間、5%二酸化炭素環境下でインキュベートし、細胞を遊走させた。グルタルアルデヒド固定及びクリスタルバイオレット染色の後、各ウェルの任意に選んだ5ヶ所の範囲について、顕微鏡(400倍率、Olympus IX71)にて観察した。下層へ遊走した細胞の数を数え、平均値を算出した。3連実験を行い、各実験は2回繰り返した。
指数増殖期のヒト肺腺癌A549腫瘍細胞(ATCC受託番号CCL−185)を6〜8週齢のヌードマウス(Vital River Laboratory Animal Technology Co., Ltd)に皮下接種した。腫瘍容積が100mm3に達したとき、腫瘍保有ヌードマウスを4群に分けた。(1)陰性対照:生理食塩水で処理を行う。(2)NT群:ES処理は行わず、NT(毎日、6mg/kg、腹腔内注射)で処理を行う。(3)ES群:NT処理は行わず、ES(毎日、12mg/kg、腹腔内注射)で処理を行う。(4)NT+ES群:NT(毎日、6mg/kg、腹腔内注射)及びES(毎日、12mg/kg、腹腔内注射)で併用処理を行う。14日間毎日の注射を行った後、マウスを屠殺し、腫瘍の重量及び容積を測定した。対照群に比べて、NT処理は腫瘍の成長に影響を及ぼさず、ES処理は腫瘍の成長を40%阻害するという結果が示された。NT+ES処理は、腫瘍の成長に対するESの阻害効果を高めた(阻害率60%)。これらの結果より、NTは腫瘍の成長におけるESの阻害効力を増強することが実証された(図4A)。体重、摂食、及び日常行動に関して、すべての群の動物において異常な変化は観察されなかった。
指数増殖期のEGFR発現A549細胞を90%コンフルエントに達するまで培養し、その後以下のようにNTを含むDMEM培地で前処理をした。NT保存溶液を最終濃度が0μg/mL、25μg/mL、又は50μg/mLになるように培地に添加し、その後、培養液を、NT前処理として、37℃で20分間、5%二酸化炭素環境下でインキュベートした。前処理後、EGFRモノクローナル抗体(セツキシマブ、Merck)保存溶液(5mg/ml)を最終濃度5μg/mLになるように培地に添加した。培養液を、その後37℃で30分間、5%二酸化炭素環境下でインキュベートし、内皮細胞によるEGFRモノクローナル抗体の内部移行を行った。処理後、培地を取り除き、内皮細胞を氷冷したPBSで3回洗浄し、回収した。細胞におけるEGFRモノクローナル抗体の内部移行を、NTを処理しない細胞におけるEGFRモノクローナル抗体の内部移行と比べて、ウエスタンブロッティングによって調べた。セツキシマブ用量及び処理時間が同一の場合には、NT処理によって、細胞におけるセツキシマブの内部移行が有意に増加し、セツキシマブの内部移行は、NT濃度に正に相関するという結果が示された(図5A)。
Claims (25)
- 対象の標的細胞による治療薬の取り込みを増加させる医薬組成物の調製における、脂質ラフト/カベオラ依存性エンドサイトーシス経路の調節剤の使用。
- 脂質ラフト/カベオラ依存性エンドサイトーシス経路の前記調節剤が、脂質ラフト/カベオラ依存性エンドサイトーシス経路の阻害剤である、請求項1に記載の使用。
- 前記脂質ラフト/カベオラ依存性エンドサイトーシス経路の阻害剤が、ポリエン系抗真菌薬である、請求項2に記載の使用。
- 前記脂質ラフト/カベオラ依存性エンドサイトーシス経路の阻害剤が、ナイスタチン及びアムホテリシンBから選択される、請求項3に記載の使用。
- 前記脂質ラフト/カベオラ依存性エンドサイトーシス経路の阻害剤が、メチル−β−シクロデキストリン又はフィリピンである、請求項2に記載の使用。
- 前記治療薬が、脂質ラフト/カベオラ依存性エンドサイトーシス経路及びクラスリン被覆ピットエンドサイトーシス経路を介して前記標的細胞に取り込まれることができる、請求項1〜5のいずれか一項に記載の使用。
- 前記対象が、血管新生関連疾患又はリンパ脈管新生関連疾患に罹っている、請求項1〜6のいずれか一項に記載の使用。
- 前記対象が、腫瘍に罹っている、請求項1〜6のいずれか一項に記載の使用。
- 前記治療薬が、血管新生又はリンパ脈管新生阻害剤である、請求項7又は8に記載の使用。
- 前記血管新生又はリンパ脈管新生阻害剤が、天然のエンドスタチン又はヒト型組換えエンドスタチン又はその誘導体である、請求項9に記載の使用。
- 前記エンドスタチンが、配列番号1又は配列番号2に示されるアミノ酸配列を含む、請求項10に記載の使用。
- 前記エンドスタチンが、N末端に付加的なアミノ酸配列(M)GGSHHHHHを有し、配列番号3又は配列番号4に示されるアミノ酸配列を有する、請求項10に記載の使用。
- 前記エンドスタチン誘導体が、ポリエチレングリコール(PEG)修飾エンドスタチンである、請求項10〜12のいずれか一項に記載の使用。
- 前記ポリエチレングリコール(PEG)が、5〜40kDの平均分子量を有するメトキシPEGである、請求項13に記載の使用。
- 前記PEGがメトキシPEGプロピオンアルデヒドである、請求項14に記載の使用。
- 前記メトキシPEGプロピオンアルデヒドの前記平均分子量が20kDである、請求項15に記載の使用。
- 前記エンドスタチンが、N末端αアミンの部位でポリエチレングリコール(PEG)によって修飾されている、請求項13〜16のいずれか一項に記載の使用。
- 前記治療薬が、腫瘍細胞の増殖を阻害することができる抗体である、請求項8に記載の使用。
- 前記抗体が、上皮成長因子受容体(EGFR)の抗体である、請求項18に記載の使用。
- 前記抗体が、上皮成長因子受容体(EGFR)のモノクローナル抗体である、請求項18に記載の使用。
- 上皮成長因子受容体(EGFR)の前記モノクローナル抗体がセツキシマブである、請求項18に記載の使用。
- 前記腫瘍が、肺がん、膵臓がん、肝臓がん、胃がん、大腸がん、食道がん、鼻咽頭癌、悪性メラノーマ、骨がん、リンパ腫、乳がん、子宮頚がん、前立腺がん、血管腫、神経内分泌腫瘍、口腔がん、肉腫、腎がん、及び胆のうがんからなる群から選択される、請求項8〜21のいずれか一項に記載の使用。
- 脂質ラフト/カベオラ依存性エンドサイトーシス経路の前記調節剤が、静脈注射、点滴静脈注射、皮下注射、筋肉注射、腹腔注射、皮下包埋、経皮吸収、及び肝動脈注射からなる群から選択される非経口的な経路を介して投与される、請求項1〜22のいずれか一項に記載の使用。
- 脂質ラフト/カベオラ依存性エンドサイトーシス経路の前記調節剤が、リポソームカプセル化の形態に調製される、請求項23に記載の使用。
- (a)請求項10〜17のいずれか一項に記載のエンドスタチン又は請求項18〜21のいずれか一項に記載の抗体と、
(b)請求項2〜5のいずれか一項に記載の脂質ラフト/カベオラ依存性エンドサイトーシス経路の阻害剤と
を含む医薬組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110085338.8A CN102698270B (zh) | 2011-03-28 | 2011-03-28 | 一种增强靶细胞摄取治疗剂的方法和药物组合物 |
CN201110085338.8 | 2011-03-28 | ||
PCT/CN2012/073202 WO2012130141A1 (zh) | 2011-03-28 | 2012-03-28 | 一种增强靶细胞摄取治疗剂的方法和药物组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2014510737A true JP2014510737A (ja) | 2014-05-01 |
JP6114940B2 JP6114940B2 (ja) | 2017-04-19 |
Family
ID=46891512
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014501425A Active JP6114940B2 (ja) | 2011-03-28 | 2012-03-28 | 標的細胞による治療薬の取り込みを高めるための方法及び組成物 |
Country Status (7)
Country | Link |
---|---|
US (1) | US9364493B2 (ja) |
EP (1) | EP2702997B1 (ja) |
JP (1) | JP6114940B2 (ja) |
CN (1) | CN102698270B (ja) |
AU (1) | AU2012237786B2 (ja) |
CA (1) | CA2837122C (ja) |
WO (1) | WO2012130141A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7492687B2 (ja) | 2017-07-30 | 2024-05-30 | 清華大学 | Dna-pkcsを阻害するための薬物治療 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114558111A (zh) * | 2014-11-03 | 2022-05-31 | 清华大学 | 一种抑制脂肪细胞分化和胰岛素耐受的药物 |
CN105646667A (zh) * | 2016-04-06 | 2016-06-08 | 南京安吉生物科技有限公司 | 聚乙二醇修饰的血管生成抑制剂hm-1及其应用 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4812312A (en) * | 1987-03-03 | 1989-03-14 | Board Of Regents Of The University Of Texas System | Liposome-incorporated nystatin |
EP1743031A4 (en) * | 2004-04-26 | 2008-05-28 | Childrens Medical Center | BLOOD PLATE BIOMARKERS FOR THE DETECTION OF ILLNESSES |
JP2006249017A (ja) * | 2005-03-11 | 2006-09-21 | Chiba Univ | 軸索再生促進剤 |
CN1891717A (zh) * | 2005-07-08 | 2007-01-10 | 南京大学 | 内皮抑素的化学修饰方法及其应用 |
CN100475270C (zh) * | 2006-01-20 | 2009-04-08 | 清华大学 | 一种治疗肿瘤的药物及其应用 |
WO2008144616A1 (en) * | 2007-05-18 | 2008-11-27 | Heidi Kay | Lipid raft, caveolin protein, and caveolar function modulation compounds and associated synthetic and therapeutic methods |
DE102008043724A1 (de) * | 2008-11-13 | 2010-05-20 | Biotronik Vi Patent Ag | Erhöhung der Effizienz pharmazeutische Wirkstoffe-freisetzender Medizinprodukte durch Kombination mit einem Inhibitor des Transportproteins P-Glycoprotein |
WO2010141097A2 (en) * | 2009-06-05 | 2010-12-09 | The Trustees Of Columbia Univerity In The City Of New York | Pegylated human apoa-1 and process for production thereof |
WO2013142184A1 (en) * | 2012-03-19 | 2013-09-26 | Yale University | Antimicrobial compositions and methods |
-
2011
- 2011-03-28 CN CN201110085338.8A patent/CN102698270B/zh active Active
-
2012
- 2012-03-28 CA CA2837122A patent/CA2837122C/en active Active
- 2012-03-28 EP EP12765089.3A patent/EP2702997B1/en active Active
- 2012-03-28 JP JP2014501425A patent/JP6114940B2/ja active Active
- 2012-03-28 WO PCT/CN2012/073202 patent/WO2012130141A1/zh active Application Filing
- 2012-03-28 AU AU2012237786A patent/AU2012237786B2/en active Active
- 2012-03-28 US US14/008,428 patent/US9364493B2/en active Active
Non-Patent Citations (10)
Title |
---|
JPN6014048179; Cancer Chemother. Pharmacol. Vol.40, 1997, pp.385-390 * |
JPN6014048183; Pharmacology Vol.24, 1978, pp.2-16 * |
JPN6014048190; Cancer Res. Vol.69 No.13, 2009, pp.5610-5617 * |
JPN6014048193; Biochim. Biophys. Acta Vol.864, 1986, pp.257-304 * |
JPN6014048194; 血管医学 Vol.3 No.6, 2002, pp.39-45 * |
JPN6014048195; Mol. Pharmacol. Vol.74 No.1, 2008, pp.101-108 * |
JPN6014048196; J. Biol. Chem. Vol.285 No.49, 2010, pp.38543-38554 * |
JPN6015042814; Cancer Res. Vol.60, 2000, pp.2190-2196 * |
JPN6015042816; Cancer Lett. Vol.292, 2010, pp.32-40 * |
JPN6015042818; J. Biol. Chem. Vol.278 No.39, 2003, pp.37895-37901 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7492687B2 (ja) | 2017-07-30 | 2024-05-30 | 清華大学 | Dna-pkcsを阻害するための薬物治療 |
Also Published As
Publication number | Publication date |
---|---|
AU2012237786A1 (en) | 2013-11-14 |
US20140335152A2 (en) | 2014-11-13 |
AU2012237786B2 (en) | 2015-10-15 |
EP2702997B1 (en) | 2019-03-13 |
CA2837122C (en) | 2018-01-02 |
CN102698270B (zh) | 2016-02-03 |
US9364493B2 (en) | 2016-06-14 |
JP6114940B2 (ja) | 2017-04-19 |
EP2702997A1 (en) | 2014-03-05 |
CN102698270A (zh) | 2012-10-03 |
US20140147492A1 (en) | 2014-05-29 |
EP2702997A4 (en) | 2014-12-31 |
WO2012130141A1 (zh) | 2012-10-04 |
CA2837122A1 (en) | 2012-10-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Jin et al. | Targeting lipid metabolism to overcome EMT-associated drug resistance via integrin β3/FAK pathway and tumor-associated macrophage repolarization using legumain-activatable delivery | |
Said et al. | Absence of host-secreted protein acidic and rich in cysteine (SPARC) augments peritoneal ovarian carcinomatosis | |
Li et al. | Extracellular Hsp90 (eHsp90) as the actual target in clinical trials: intentionally or unintentionally | |
Ju et al. | Octreotide-modified liposomes containing daunorubicin and dihydroartemisinin for treatment of invasive breast cancer | |
Zheng et al. | Ang-(1-7) promotes the migration and invasion of human renal cell carcinoma cells via Mas-mediated AKT signaling pathway | |
Wang et al. | N2E4, a monoclonal antibody targeting neuropilin-2, inhibits tumor growth and metastasis in pancreatic ductal adenocarcinoma via suppressing FAK/Erk/HIF-1α signaling | |
EP3302557B1 (en) | Antagonist of collagen for enhancing the therapeutic activity of an immune checkpoint inhibitor in the treatment of melanoma | |
JP2021527651A (ja) | C/EBPアルファsaRNAを含む併用療法 | |
JP6114940B2 (ja) | 標的細胞による治療薬の取り込みを高めるための方法及び組成物 | |
Wu et al. | A novel humanized MUC1 antibody–drug conjugate for the treatment of trastuzumab-resistant breast cancer | |
Luo et al. | Fucoidan inhibits EGFR redistribution and potentiates sorafenib to overcome sorafenib-resistant hepatocellular carcinoma | |
Ni et al. | Alkaloid derivative ION-31a inhibits breast cancer metastasis and angiogenesis by targeting HSP90α | |
Lee et al. | Intracellular KRAS-specific antibody enhances the anti-tumor efficacy of gemcitabine in pancreatic cancer by inducing endosomal escape | |
EP3969027A1 (en) | Polypeptides for treatment of cancer | |
JP2022545429A (ja) | がん治療のための化学療法剤とα-ラクトグロブリン-オレイン酸複合体との組合せ | |
EP3960852A1 (en) | Peptides for the treatment of cancer | |
JP6027137B2 (ja) | Egfr及びガングリオシドn−グリコリルgm3(neugcgm3)を発現する腫瘍の治療のための医薬組成物 | |
Huang et al. | Synthetically Lethal Biomimetic Nutri-hijacker Hitchhikes and Reprograms KRAS Mutation-Driven Metabolic Addictions for Pancreatic Ductal Adenocarcinoma Treatment | |
Bader | Targeting Cell Surface GRP78 for Specific Nanoparticle Mediated Drug Delivery to Breast Cancer | |
TWI808063B (zh) | 治療或預防癌症的方法 | |
Zhao | Development of Targeted siRNA Therapeutics for Triple Negative Breast Cancer and Liver Fibrosis | |
Guo et al. | Therapeutic Targeting Tongue Squamous Cell Carcinoma via ICAM1 Antibody-Drug Conjugates in Preclinical Models | |
Li | Development of Nanomedicine to Simultaneously Target Pancreatic Cancer Cells and Stroma | |
Wang et al. | Fusion of dual-targeting peptides with MAP30 promotes the apoptosis of MDA-MB-231 breast cancer cells | |
Bell | Targeting Cell Surface GRP78 Receptor with Hybrid Peptides as Drug Carriers |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20141118 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20150218 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20150318 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20150417 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150515 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20151027 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160229 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20160408 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20160610 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20170223 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6114940 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |